Headache Unit, Department of Neurology. Hospital, Clínico Universitario de Valladolid, Avenida Ramón y Cajal 3, 47005, Valladolid, Spain.
Department of Mental Health and Substance Use, World Health Organization, Geneve, Switzerland.
J Neurol. 2021 Nov;268(11):3947-3960. doi: 10.1007/s00415-021-10588-5. Epub 2021 May 22.
The COVID-19 pandemic leads to disruptions of health services worldwide. To evaluate the particular impact on neurological services a rapid review was conducted.
Studies reporting the provision of neurological services during the pandemic and/or adopted mitigation strategies were included in this review. PubMed and World Health Organization's (WHO) COVID-19 database were searched. Data extraction followed categories used by WHO COVID-19 pulse surveys and operational guidelines on maintaining essential health services during COVID-19.
The search yielded 1101 articles, of which 369 fulfilled eligibility criteria, describing data from 210,419 participants, being adults (81%), children (11.4%) or both (7.3%). Included articles reported data from 105 countries and territories covering all WHO regions and World Bank income levels (low income: 1.9%, lower middle: 24.7%, upper middle: 29.5% and high income; 44.8%). Cross-sectoral services for neurological disorders were most frequently disrupted (62.9%), followed by emergency/acute care (47.1%). The degree of disruption was at least moderate for 75% of studies. Travel restrictions due to lockdowns (81.7%) and regulatory closure of services (65.4%) were the most commonly reported causes of disruption. Authors most frequently described telemedicine (82.1%) and novel dispensing approaches for medicines (51.8%) as mitigation strategies. Evidence for the effectiveness of these measures is largely missing.
The COVID-19 pandemic affects all aspects of neurological care. Given the worldwide prevalence of neurological disorders and the potential long-term neurological consequences of COVID-19, service disruptions are devastating. Different strategies such as telemedicine might mitigate the negative effects of the pandemic, but their efficacy and acceptability remain to be seen.
COVID-19 大流行导致全球卫生服务中断。为了评估其对神经科服务的特殊影响,我们进行了快速审查。
本综述纳入了报告大流行期间提供神经科服务和/或采取缓解策略的研究。检索了 PubMed 和世界卫生组织(WHO)COVID-19 数据库。数据提取遵循 WHO COVID-19 脉搏调查和在 COVID-19 期间维持基本卫生服务的操作指南中使用的类别。
搜索共产生了 1101 篇文章,其中 369 篇符合入选标准,描述了来自 210419 名参与者的数据,其中 81%为成年人,11.4%为儿童,7.3%为两者兼有。纳入的文章报告了来自 105 个国家和地区的数据,涵盖了所有世卫组织区域和世界银行收入水平(低收入:1.9%,中下收入:24.7%,中上收入:29.5%和高收入:44.8%)。神经障碍的跨部门服务最常受到干扰(62.9%),其次是紧急/急性护理(47.1%)。至少有 75%的研究报告的中断程度为中度或以上。由于封锁导致的旅行限制(81.7%)和服务监管关闭(65.4%)是最常报告的中断原因。作者最常描述远程医疗(82.1%)和新型药品配药方法(51.8%)作为缓解策略。这些措施的有效性的证据在很大程度上是缺失的。
COVID-19 大流行影响神经科护理的各个方面。鉴于神经障碍的全球流行和 COVID-19 的潜在长期神经后果,服务中断是毁灭性的。远程医疗等不同策略可能减轻大流行的负面影响,但它们的疗效和可接受性仍有待观察。